CLINICAL TRIALS PROFILE FOR THROMBIN, TOPICAL (BOVINE)
✉ Email this page to a colleague
All Clinical Trials for thrombin, topical (bovine)
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00196534 ↗ | A Study to Compare Human Thrombin Against Bovine Thrombin in Its Ability to Stop Bleeding After Surgery | Completed | OMRIX Biopharmaceuticals | Phase 3 | 2004-11-01 | The purpose of this study is to see if Human Thrombin is as effective as Bovine Thrombin in stopping surgical bleeding within 10 minutes of application. |
| NCT00196534 ↗ | A Study to Compare Human Thrombin Against Bovine Thrombin in Its Ability to Stop Bleeding After Surgery | Completed | Ethicon, Inc. | Phase 3 | 2004-11-01 | The purpose of this study is to see if Human Thrombin is as effective as Bovine Thrombin in stopping surgical bleeding within 10 minutes of application. |
| NCT00245336 ↗ | Study of Recombinant Human Thrombin for Bleeding During Surgery | Completed | ZymoGenetics | Phase 3 | 2005-10-01 | The purpose of this study is to determine whether recombinant human Thrombin (rhThrombin) is effective in stopping bleeding during surgery, in comparison with bovine thrombin. |
| NCT00645840 ↗ | Anti-inflammatory Therapy With Anakinra in Newly Diagnosed Type 1 Diabetes | Completed | Children's Medical Center Dallas | Phase 1/Phase 2 | 2008-03-01 | The purpose of this study is to determine whether control of inflammatory pathways mediated by IL-1 beta using the IL-1 receptor antagonist anakinra will yield measurable decreases in expression of genes that are otherwise overexpressed as a consequence of IL-1 beta effects in children with newly diagnosed type 1 diabetes. Ultimately, we believe that control of IL-1 beta pathways will be associated with preserved insulin secretory capacity. |
| NCT00645840 ↗ | Anti-inflammatory Therapy With Anakinra in Newly Diagnosed Type 1 Diabetes | Completed | University of Texas Southwestern Medical Center | Phase 1/Phase 2 | 2008-03-01 | The purpose of this study is to determine whether control of inflammatory pathways mediated by IL-1 beta using the IL-1 receptor antagonist anakinra will yield measurable decreases in expression of genes that are otherwise overexpressed as a consequence of IL-1 beta effects in children with newly diagnosed type 1 diabetes. Ultimately, we believe that control of IL-1 beta pathways will be associated with preserved insulin secretory capacity. |
| NCT02152917 ↗ | Comparison of Floseal® and Tranexamic Acid on Bleeding Control After Total Knee Arthroplasty | Unknown status | University of Sao Paulo General Hospital | Phase 4 | 2014-02-01 | The total knee arthroplasty (TKA) is a well established option for the treatment of osteoarthritis in this joint. Nevertheless, there are still some concerns related to the peri-operative management of elderly patients, highlighting the complications related to medical comorbidity and bleeding produced by surgery. One of the proposed methods to decrease postoperative bleeding, which has been accumulating favorable evidence, is the use of tranexamic acid (TA). Several studies (including prospective randomized trials with placebo group) showed excellent results with TA intravenous administration during TKA, reducing the amount of bleeding, the drop in hemoglobin and the need for blood transfusion. Another alternative to minimize bleeding is the use of topical hemostatic agent Floseal®, composed of thrombin and bovine gelatin. This substance has presented significant benefits on bleeding control in several areas of medicine, including orthopedic surgery, but no action has yet been established in TKA. The main objective is to evaluate the amount of bleeding, the drop in hemoglobin and the need for blood transfusion after TKA, comparing the use of TA, Floseal® and a control group. The secondary objective is to evaluate the rate of adverse events in the studied groups. |
| NCT02831374 ↗ | Effectiveness of Platelet Rich Plasma in Wound Healing | Completed | Linyi People's Hospital | Early Phase 1 | 2015-10-01 | Purpose: This prospective randomized comparative clinical study was conducted to assess the effect of platelet-rich plasma (PRP) gel on soft tissue healing and bone regeneration potential on lower third molar extraction sockets. Methods: For the study, 50 Patients (37 male, 13 female) requiring surgical removal of a lower impacted third molar and who fulfilled the inclusion criteria were recruited. The patients were categorized into two groups, Group A and Group B. For each group 25 patients were randomly allocated. The predictor variable in Group A was the application of PRP Gel whereas in Group B had no PRP. Postoperative pain, swelling, trismus, soft tissue healing and osseous regeneration was assessed using standard methods. These outcome variables were assessed on 1, 3-, 5-, 7-, and 14-postoperative day. Patients were recalled at the 4th, 10th, and 16th postoperative week for assessment of bone healing. The data were recorded and tabulated. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for thrombin, topical (bovine)
Condition Name
Clinical Trial Locations for thrombin, topical (bovine)
Trials by Country
Clinical Trial Progress for thrombin, topical (bovine)
Clinical Trial Phase
Clinical Trial Sponsors for thrombin, topical (bovine)
Sponsor Name
